In a large single-arm phase 2 trial, the anti-PD-1 inhibitor tislelizumab combined with the next-generation BTK inhibitor zanubrutinib had an overall response rate of 58.3% and was well tolerated in patients with Richter’s transformation.
- Othman Al-Sawaf
- Rudy Ligtvoet
- Barbara Eichhorst